GlassScriptPhysician profile
Maryann Mikhail
NPI 1437301645
$2,227.18
in general payments reported to CMS, 2019-2025
29 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $64.79 · 2021: $283 · 2022: $380 · 2023: $318 · 2024: $233 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $288.15 | 2019-2025 | Dysport |
| Regeneron Healthcare Solutions, INC. | $185.39 | 2019-2025 | Dupixent, Libtayo |
| Allergan, INC. | $171.02 | 2019-2021 | |
| Janssen Biotech, INC. | $158.21 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Celgene Corporation | $151.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $142.72 | 2019-2025 | |
| Abbvie INC. | $132.18 | 2019-2025 | |
| Lilly USA, LLC | $128.65 | 2019-2025 | Ebglyss, Taltz |
| Pfizer INC. | $110.33 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $109.17 | 2019-2025 | |
| Amgen INC. | $86.45 | 2021-2023 | Otezla |
| Leo Pharma INC. | $70.96 | 2021-2023 | Adbry |
| Dermira, INC. | $63.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.40 | 2024 | Sotyktu |
| Solta Medical, A Division of Bausch Health US, LLC | $43.70 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $38.44 | 2019 | |
| Strata Skin Sciences, INC. | $38.15 | 2024-2025 | Xtrac |
| Biofrontera INC. | $33.30 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $31.66 | 2023 | Seysara |
| Promius Pharma LLC | $28.75 | 2019 | |
| Verrica Pharmaceuticals INC. | $26.71 | 2024 | Ycanth |
| Incyte Corporation | $24.93 | 2023 | Opzelura |
| Genzyme Corporation | $23.94 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.50 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $18.75 | 2019 | |
| Aclaris Therapeutics, INC. | $15.04 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $14.24 | 2021 | |
| Epi Health, LLC | $11.95 | 2021 | |
| Journey Medical Corporation | $8.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryann Mikhail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.